Patents by Inventor Nicolai Tvermoes

Nicolai Tvermoes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20120040891
    Abstract: Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
    Type: Application
    Filed: August 31, 2011
    Publication date: February 16, 2012
    Inventors: John J. Dwyer, Brian L. Bray, Stephen E. Schneider, Huyi Zhang, Nicolai A. Tvermoes, Barbara E. Johnston, Paul E. Friedrich
  • Patent number: 8034899
    Abstract: Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: October 11, 2011
    Assignee: Trimeris, Inc.
    Inventors: John Dwyer, Brian L. Bray, Stephen E. Schneider, Huyi Zhang, Nicolai A. Tvermoes, Barbara E. Johnston, Paul E. Friedrich
  • Publication number: 20100261876
    Abstract: Provided herein are methods for synthesis of peptides. In particular, provided herein are methods of synthesis for therapeutic antiviral peptides.
    Type: Application
    Filed: September 25, 2008
    Publication date: October 14, 2010
    Inventors: Brian L. Bray, Barbara E. Johnston, Stephen E. Schneider, Nicolai A. Tvermoes, Huyi Zhang, Paul E. Friedrich
  • Publication number: 20100016225
    Abstract: Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
    Type: Application
    Filed: June 4, 2009
    Publication date: January 21, 2010
    Inventors: Brian Bray, Myung-Chol kang, Nicolai Tvermoes, Daniel Kinder, John William Lackey, Huyi Zhang
  • Patent number: 7556813
    Abstract: Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: July 7, 2009
    Assignee: Trimeris, Inc.
    Inventors: Brian Bray, Myung-Chol Kang, Nicolai Tvermoes, Daniel Kinder, John William Lackey, Huyi Zhang
  • Publication number: 20090105143
    Abstract: Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
    Type: Application
    Filed: October 20, 2008
    Publication date: April 23, 2009
    Inventors: John J. Dwyer, Brian L. Bray, Stephen E. Schneider, Huyi Zhang, Nicolai A. Tvermoes, Barbara E. Johnston, Paul E. Friedrich
  • Publication number: 20070179278
    Abstract: Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions.
    Type: Application
    Filed: February 2, 2007
    Publication date: August 2, 2007
    Inventors: John Dwyer, Brian Bray, Stephen Schneider, Huyi Zhang, Nicolai Tvermoes, Barbara Johnston, Paul Friedrich
  • Publication number: 20060142365
    Abstract: The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.
    Type: Application
    Filed: February 2, 2006
    Publication date: June 29, 2006
    Inventors: John Lackey, Daniel Kinder, Nicolai Tvermoes
  • Patent number: 7030150
    Abstract: The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.
    Type: Grant
    Filed: May 9, 2002
    Date of Patent: April 18, 2006
    Assignee: Trimeris, Inc.
    Inventors: John William Lackey, Daniel S Kinder, Nicolai A Tvermoes
  • Publication number: 20040122214
    Abstract: Provided are conjugates comprising a polymer having operably bound thereto no less than two molecules of synthetic peptide derived from HIV gp41; methods of using these conjugates to inhibit transmission of HIV to a target cell by adding an amount of effective to inhibit infection of the cell by the virus; and methods of producing the conjugates by operably binding each molecule of synthetic peptide, via a reactive functionality, to the polymer.
    Type: Application
    Filed: September 24, 2003
    Publication date: June 24, 2004
    Inventors: Brian Bray, Myung-Chol Kang, Nicolai Tvermoes, Daniel Kinder, John William Lackey
  • Publication number: 20030119754
    Abstract: The present invention relates to novel benzimidazole compounds that have useful antiviral activity. More specifically, the invention encompasses benzimidazole compounds that inhibit membrane fusion associated events such as viral transmission, reduce viral load or otherwise treat viral infections. The invention also encompasses the use of benzimidazole compounds as inhibitors of membrane fusion associated events, such as viral transmission. In another embodiment, the invention encompasses processes for making benzimidazole compounds, methods of using the benzimidazole compounds and compositions comprising the benzimidazole compounds. Finally, the invention provides methods for treating, preventing or ameliorating symptoms associated with respiratory infection, particularly that caused by Respiratory Syncytial Virus utilizing the novel benzimidazole compounds of the invention.
    Type: Application
    Filed: May 9, 2002
    Publication date: June 26, 2003
    Inventors: John William Lackey, Daniel S. Kinder, Nicolai A. Tvermoes